Sandoz, Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100 mg Extended Release Tablets Due to Presence of a Nitrosamine Impurity

medMedication SafetyHealthcare ProfessionalEducators and caregivers
Written by Denise Kolakowski

The presence of a nitrosamine (N-methyl-N-nitroso-2-[(2-methylphenyl)phenylmethoxy]ethanamine (NMOA or Nitroso-Orphenadrine)) impurity was detected in the lots during recent testing.

Learn more from the FDA
Denise Kolakowski
Previous

Plastikon Healthcare Issues Voluntary Nationwide Recall of Several Common Over the Counter Medications Due to Microbial Contamination
Next

Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (Epinephrine) Injection for Potential Manufacturing Defect